 WARMER, Pa., July 29, 2020 GLOBE NEWSWIRE -- Arbutus Biopharma Corporation Nasdaq: ABUS, a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chronic hepatitis B virus HBV infection, as well as therapies to treat coronaviruses including COVID-19, today announced that it has scheduled its second quarter financial results, conference call and webcast for Friday, August 7, 2020. The schedule for the press release and conference callwebcast are as follows: Q2 2020 Press Release: August 7, 2020 at 7:30 a.m. ET Q2 2020 Conference CallWebcast: August 7, 2020 at 8:45 a.m. ET Domestic Dial-In Number: 866 393-1607 International Dial-In Number: 914 495-8556 Conference ID Number: 4974547 A live webcast of the conference call can be accessed through the Investors section of Arbutus website at or directly at Live Webcast.An archived webcast will be available on the Arbutus website after the event. Alternatively, you may access a replay of the conference call by calling 855 859-2056 or 404 537-3406, and reference conference ID: 4974547.About ArbutusArbutus Biopharma Corporation is a publicly traded Nasdaq: ABUS biopharmaceutical company dedicated to discovering, developing and commercializing a cure for people with chronic hepatitis B virus HBV infection. The Company is advancing multiple drug product candidates that may be combined into a potentially curative regimen for chronic HBV infection. Arbutus has also initiated a drug discovery and development effort for treating coronaviruses including COVID-19. For more information, visit Information Investors and MediaWilliam H. Collier President and CEO Phone: 267-469-0914 Email: Pam Murphy Investor Relations Consultant Phone: 267-469-0914 Email: 